Information about NationDrugs.to
List of countries where we can ship Paraplatin:
Latest news releases on Paraplatin:
1 of 21 Rx only PARAPLATIN® (carboplatin) Injection WARNING PARAPLATIN (carboplatin) Injection should be administered under the supervision of a
Carboplatin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. Carboplatin can cause a severe decrease in the number of blood cells in your bone marrow. This increases the risk that you will
Carboplatin. Carboplatin is a chemotherapy drug used for treatment of many types of cancer. The U.S. Food and Drug Administration approved carboplatin for use treating patients with ovarian and non-small cell lung cancer, and oncologists often use carboplatin "off-label" for other cancers.
Medscape - Advanced ovarian carcinoma dosing for Paraplatin (carboplatin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
Find patient medical information for Isotretinoin Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.
Carboplatin (Paraplatin) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of ovarian and other cancers
Carboplatin is a chemotherapy drug used to treat ovarian and lung cancer. It may also be used to treat other cancers. It is best to read this information with our general information about chemotherapy and the type of cancer you have.
This page contains brief information about carboplatin and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4. A DLT was defined as any of the following events: Grade 4 non-hematologic toxicity (not laboratory); Grade 4 hematologic toxicity lasting ≥7 days; Grade 3 non-hematologic toxicity (not laboratory, specifically nausea, vomiting and ...
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly